Frailty, Inflammation, and Stem Cell Functionality in Chronic Kidney Disease
试验速览
- 阶段
- 2 期
- 状态
- 暂停
- 发起方
- Mayo Clinic
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Change in inflammatory markers including C-reactive protein
研究概览
简要总结
The proposed studies will examine the effect of fisetin on adipose tissue-derived mesenchymal stem/stromal cell function, kidney function, markers of inflammation, and physical function in individuals with advanced chronic kidney disease.
详细描述
The proposed studies will examine the effect of fisetin on adipose tissue-derived mesenchymal stem/stromal cell function, kidney function, markers of inflammation, and physical function in individuals with advanced chronic kidney disease, particularly diabetic kidney disease. This study will involve a single 2-day oral treatment regimen with fisetin or placebo. Study subjects will be randomized 2:1 to study drug or placebo. Study visits will consist of blood, urine, and abdominal wall skin and subcutaneous fat samplings in addition to testing of physical strength at given time points. Subjects will be followed for a total of 12 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 40 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 40-80 years
- •Chronic kidney disease estimated glomerular filtration rate (eGFR) 15-60 ml/min/1.73m2
- •For the diabetic kidney disease (DKD) subgroup: Diabetes mellitus (on medication)
排除标准
- •Hemoglobin A1c>11% at screening for the DKD subgroup
- •Body weight >150 kg or body mass index>50
- •Pregnancy
- •Active glomerulonephritis treated with immunosuppressive therapy
- •Solid organ transplantation (eg. kidney, pancreas, liver, lung, heart)
- •Active immunosuppression therapy
- •History of active substance abuse (including alcohol) within the past 2 years,
- •Current alcohol abuse (>3 alcoholic beverages/day or >21 per week),
- •Human immunodeficiency virus infection
- •Active hepatitis B or C infection
- •Total bilirubin >2x upper limit of normal
- •Uncontrolled psychiatric disorder
- •Uncontrolled systemic lupus erythematosus
- •Uncontrolled pleural/pericardial effusions or ascites
- •New invasive cancer except non-melanoma skin cancers
- •Invasive fungal or viral infection
- •Inability to tolerate oral medications
- •Known hypersensitivity or allergy to Fisetin
- •Subjects taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6CYP2C9, CYP2C19, CYP1A2, Other (OATP1B1) (Unless willing and able to stop or modify the dosing of the drug) or strong inhibitors or inducers of CYP3A4 (e.g. cyclosporine, tacrolimus or sirolimus).
- •Tyrosine kinase inhibitor therapy
- •Subjects on therapeutic doses of anticoagulants (e.g., warfarin, heparin, low molecular weight heparin, factor Xa inhibitors, etc.).
- •Subjects on full-dose 325 mg aspirin or other anti-platelet agents (eg. clopidogrel) daily who are unable or unwilling to reduce or hold therapy prior to and during the 2-day drug dosing. Subjects may continue their previous regimen on day
- •Baby aspirin (81 mg), if necessary for cardioprotection, will be allowed but encouraged to hold.
- •Subjects taking proton pump inhibitors who are unable or unwilling to reduce or hold therapy 2 days prior to and during the 2-day drug dosing. Subjects taking H2-antagonists and unwilling to discontinue therapy for 2 weeks before and one week following enrollment. (See Appendix 4)
- •Subjects taking glimepiride or glyburide for diabetes therapy who are unable or unwilling to reduce or hold therapy prior to and during the 2-day drug dosing.
- •Subjects taking the following antimicrobial agents: Aminoglycosides, Azole antifungals (fluconazole, miconazole, voriconazole, itraconazole), Macrolides (clarithromycin, erythromycin), Antivirals (nelfinavir, indinavir, saquinavir, ritonavir, elbasvir/grazoprevir), Rifampin
- •Corrected QT interval (QTc) >450 msec
- •Tobacco use (smoking or chewing; Unless subject willing to reduce use by 50% prior to and during the study) - see Behavioral Modification information below.
- •Inability to give informed consent
- •Presence of any condition that the Investigator believes would put the subject at risk or would preclude the patient from successfully completing all aspects of the trial
研究组 & 干预措施
Placebo
Placebo capsules orally for 2 consecutive days
干预措施: Placebo oral capsule (Drug)
Treatment
Fisetin 20 mg/kg/day, orally for 2 consecutive days
干预措施: Fisetin (Dietary Supplement)
结局指标
主要结局
Change in inflammatory markers including C-reactive protein
时间窗: 14 days
To examine the effect of study drug (compared to placebo) on markers of inflammation in skin, fat, plasma, and urine measured at baseline and day 14
Effect on Mesenchymal stem cell function including cell migration
时间窗: 14 days
To examine the effect of study drug (compared to placebo) on mesenchymal stem cell function and vitality measured at baseline and day 14
次要结局
- Kidney function including estimated glomerular filtration rate(4 months)
- Kidney function including urine protein excretion rate(4 months)
- Effect on measures of Frailty including Fried Criteria(4 months)
- Number of participants with treatment-related adverse events including hospitalization(12 months)
研究者
LaTonya J. Hickson
Principal Investigator
Mayo Clinic